NASDAQ:IMRN - Nasdaq - US45254U1016 - ADR - Currency: USD
Overall IMRN gets a fundamental rating of 3 out of 10. We evaluated IMRN against 556 industry peers in the Biotechnology industry. While IMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMRN has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -60.42% | ||
ROE | -71.11% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 67.47% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 6.8 | ||
Quick Ratio | 5.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.74
-0.01 (-0.57%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.3 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.45 | ||
P/tB | 1.45 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -60.42% | ||
ROE | -71.11% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 67.47% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 6.8 | ||
Quick Ratio | 5.92 | ||
Altman-Z | -4.28 |